Medical weight loss is supervised treatment for obesity that may include prescription medicine, nutrition and activity plans, and regular check-ins with a licensed clinician.
Nearly two in five adults
CDC PLACES estimates adult obesity at 38.2% and diagnosed diabetes at 13.0% for Indianapolis in 2023 [1]. Marion County as a whole is almost identical, at 38.3% obesity and 13.0% diabetes [4]. A high local rate does not mean medicine is right for any one person; a prescriber weighs your BMI, conditions and goals.
Sponsored placement: open.
One local practice can be featured here. This is a paid, labeled placement and never an endorsement.
Feature your practice in Indianapolis, from $300 a month.
This box holds a paid ad from a local practice. It is labeled sponsored and is not an editorial pick.
A note on "city (balance)"
Census and CDC report Indianapolis as "city (balance)", which leaves out separately incorporated towns inside Marion County [5]. That is why the city population is 901,116 rather than the full county figure [5]. If you live in one of those towns, the Marion County numbers fit you better.
Paying for treatment in Indiana
Indiana was not on KFF's January 2026 list of 13 Medicaid programs covering GLP-1s for obesity [2]. Lilly, citing an IFEBP survey, says about half of people with employer coverage lack coverage for obesity drugs [6]. Medicare Part D enrollees who meet BMI criteria can use the Medicare GLP-1 Bridge, a $50 monthly copay for Wegovy, Foundayo or the Zepbound KwikPen through December 31, 2027 [7]. See insurance and Medicare coverage.
| Option | Starting dose | Maintenance dose | Source |
|---|---|---|---|
| Foundayo pill | $149 | $299 | [8] |
| Wegovy pill | $149 | $299 | [3] |
| Wegovy pen | $199 for first two fills, then $349 | $349 | [3] |
| Zepbound | $299 | $449 (refilled within 45 days) | [9] |
Hospital systems
The city's large systems include Indiana University Health and Eskenazi Health. We could not confirm a medical weight loss program price at either, so call and ask what the first visit, labs and follow-ups cost and whether self-pay is accepted. Our clinic checklist lists other questions.
Plan for the long haul
In SURMOUNT-4, adults who switched from tirzepatide to placebo after 36 weeks regained 14.0% of body weight over the next year, while those who kept taking it lost another 5.5% [10]. In STEP 1, average loss on semaglutide 2.4 mg was 14.9% at 68 weeks [11]. Budget for the long term. More: medical weight loss guide, semaglutide in Indianapolis, and nearby Cincinnati, Columbus and Chicago.
Serious side effects to know
The Wegovy and Zepbound labels warn about pancreatitis; get care for severe stomach pain that will not go away [12] [13]. People also taking insulin or a sulfonylurea have a higher chance of low blood sugar. Trouble breathing or a swollen face can mean an allergic reaction. A boxed warning covers thyroid C-cell tumors; these drugs are not for people with a personal or family history of medullary thyroid carcinoma or MEN 2. Stop when pregnancy is recognized. Call 911 for emergencies.
Questions people ask
What is the obesity rate in Indianapolis?
Does Indiana Medicaid cover Wegovy or Zepbound for weight loss?
No. Indiana was not among the 13 state Medicaid programs covering GLP-1s for obesity in KFF's January 2026 count [2].
Do IU Health or Eskenazi publish weight loss program prices?
We could not find a published medical weight loss price from Indiana University Health or Eskenazi Health as of Oct 17, 2026, so ask each directly.
What is the cheapest brand weight loss drug in Indianapolis?
What happens if I stop tirzepatide?
In SURMOUNT-4, people switched to placebo regained 14.0% of body weight over about a year, while those who continued lost another 5.5% [10].
Sources
13 cited
- PLACES data, place, 2025 release: Indianapolis city (balance), IN. Centers for Disease Control and Prevention, 2025 release (2023 BRFSS).
- Medicaid coverage of and spending on GLP-1s. KFF, Jan 16, 2026.
- Wegovy self-pay offer, NovoCare Pharmacy. Novo Nordisk (NovoCare), Oct 17, 2026.
- PLACES data, county, 2025 release: Marion County, IN. Centers for Disease Control and Prevention, 2025 release (2023 BRFSS).
- QuickFacts: Indianapolis city (balance), Indiana. U.S. Census Bureau, 2025 estimates and 2020-2024 ACS; accessed 2026-10-17.
- Foundayo now available (Lilly press release citing IFEBP survey). Eli Lilly and Company, Apr 9, 2026.
- Weight loss drugs coverage (Medicare GLP-1 Bridge). Medicare.gov (CMS), accessed 2026-10-17.
- Foundayo self-pay prices on LillyDirect. Eli Lilly and Company (LillyDirect), Oct 17, 2026.
- Zepbound self-pay prices on LillyDirect. Eli Lilly and Company (LillyDirect), Oct 17, 2026.
- Continued treatment with tirzepatide for maintenance of weight reduction (SURMOUNT-4). JAMA (PubMed), 2024.
- Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine (PubMed), 2021.
- Wegovy label (injection and tablets). DailyMed, National Library of Medicine, Jun 2026.
- Zepbound (tirzepatide) prescribing information. U.S. Food and Drug Administration, Apr 2026.
This page is general information, not medical advice. Talk with a licensed clinician about your own care.